Sofosbuvir/velpatasvir or glecaprevir/pibrentasvir for treating patients with hepatitis C virus reinfection following direct‐acting antiviral‐induced sustained virologic response

Authors :: Tung-Hung Su
Chen-Hua Liu
Tai-Chung Tseng
Pei-Jer Chen
Jia-Horng Kao
Chun-Jen Liu
Source :: Advances in Digestive Medicine. 10:34-42
Publication Year :: 2022
Publisher :: Wiley, 2022.

Subjects :: Sofosbuvir
business.industry
Hepatitis C virus
General Medicine
Glecaprevir
medicine.disease_cause
Virology
Sofosbuvir/velpatasvir
Pibrentasvir
Virologic response
Medicine
Glecaprevir / pibrentasvir
business
Direct acting
medicine.drug

Tools